Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial

NCT04602117 is registered in ClinicalTrials.gov with QuantumLeap Healthcare Collaborative as lead sponsor.

NCT NCT04602117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Lead sponsor
QuantumLeap Healthcare Collaborative
Phase
Phase 1
Overall status
Withdrawn
Start date
July 28, 2021
Completion date
November 17, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, endometrium tumor, estrogen receptor positive tumor, gastroesophageal adenocarcinoma, gastroesophageal cancer, her-2 protein overexpression, her2 low, her2 low breast cancer, her2 low hr positive, her2 mutation-related tumors, her2-positive breast cancer, her2-positive gastric cancer, her2-positive metastatic breast cancer, hormone receptor negative breast carcinoma, hormone receptor-positive breast cancer, hr positive, metastatic, metastatic breast cancer, metastatic cancer, metastatic gastrointestinal carcinoid tumor, ovarian cancer, ovarian carcinoma, progesterone receptor-positive breast cancer, syd-985, syd985, triple negative breast cancer, vic-trastuzumab duocarmazine